Gout
246
23
33
162
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
61 trials with published results (25%)
Research Maturity
162 completed trials (66% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.1%
10 terminated out of 246 trials
94.2%
+7.7% vs benchmark
21%
52 trials in Phase 3/4
38%
61 of 162 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 162 completed trials
Clinical Trials (246)
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Using Gout Buddy to Enhance Gout Management
Gout in the ED and Improving Research Participation
A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients
A Clinical Trial of HEC93077 in Chinese Healthy Subjects and HUA Patients With Single or Multiple Dosing
Tahiti-families: Polynesian Families of Gout Patients
The Remote Monitoring of Gout Feasibility Study in Primary Care
the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More
Study of the Correlation Between UltraSonography and Dual-Energy Computed Tomography Assessment of Urate Deposit
Long-Term Risk of Gout in Living Kidney Donors
Epidemiology of Gout in French Polynesia
Drug-Drug Interaction Study of ABP-671 in Gout Patients
A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout